Joanna Słomko

Prof. Dr. Joanna Słomko

Collegium Medicum in Bydgoszcz
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Fernando Estévez-LópezFernando Estévez-López
Fernando Estévez-López
KMKathleen Mudie
Kathleen Mudie
Xia Wang-SteverdingXia Wang-Steverding
Xia Wang-Steverding
IBInger Johanne Bakken
Inger Johanne Bakken
AIAndrejs Ivanovs
Andrejs Ivanovs
ELEliana Lacerda
Eliana Lacerda
This review aimed at determining the prevalence and incidence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in Europe. We conducted a primary search in Scopus, PubMed and Web of Science for publications between 1994 and 15 June 2019 (PROSPERO: CRD42017078688). Additionally, we performed a backward-(reference lists) and forward-(citations) search of the works included in this review. Grey literature was addressed by contacting all members of the European Network on ME/CFS (EUROMENE). Independent reviewers searched, screened and selected studies, extracted data and evaluated the methodological and reporting quality. For prevalence, two studies in adults and one study in adolescents were included. Prevalence ranged from 0.1% to 2.2%. Two studies also included incidence estimates. In conclusion, studies on the prevalence and incidence of ME/CFS in Europe were scarce. Our findings point to the pressing need for well-designed and statistically powered epidemiological studies. To overcome the shortcomings of the current state-of-the-art, EUROMENE recommends that future research is better conducted in the community, reviewing the clinical history of potential cases, obtaining additional objective information (when needed) and using adequate ME/CFS case definitions; namely, the Centers for Disease Control & Prevention−1994, Canadian Consensus Criteria, or Institute of Medicine criteria.

5 August 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Joanna SłomkoJoanna Słomko
Joanna Słomko
Fernando Estévez-LópezFernando Estévez-López
Fernando Estévez-López
SKSławomir Kujawski
Sławomir Kujawski
MZMonika Zawadka-Kunikowska
Monika Zawadka-Kunikowska
MTMałgorzata Tafil-Klawe
Małgorzata Tafil-Klawe
PZPaweł Zalewski
Paweł Zalewski
In this study we set out to define the characteristics of autonomic subgroups of patients with Chronic Fatigue Syndrome (CFS). The study included 131 patients with CFS (Fukuda criteria). Participants completed the following screening symptom assessment tools: Chalder Fatigue Scale, Fatigue Impact Scale, Fatigue Severity Scale, Epworth Sleepiness Scales, the self-reported Composite Autonomic Symptom Scale. Autonomic parameters were measured at rest with a Task Force Monitor (CNS Systems) and arterial stiffness using an Arteriograph (TensioMed Kft.). Principal axis factor analysis yielded four factors: fatigue, subjective and objective autonomic dysfunction and arterial stiffness. Using cluster analyses, these factors were grouped in four autonomic profiles: 34% of patients had sympathetic symptoms with dysautonomia, 5% sympathetic alone, 21% parasympathetic and 40% had issues with sympathovagal balance. Those with a sympathetic-dysautonomia phenotype were associated with more severe disease, reported greater subjective autonomic symptoms with sympathetic over-modulation and had the lowest quality of life. The highest quality of life was observed in the balance subtype where subjects were the youngest, had lower levels of fatigue and the lowest values for arterial stiffness. Future studies will aim to design autonomic profile-specific treatment interventions to determine links between autonomic phenotypes CFS and a specific treatment.

13 April 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Joanna SłomkoJoanna Słomko
Joanna Słomko
Marta ZalewskaMarta Zalewska
Marta Zalewska
WNWojciech Niemiro
Wojciech Niemiro
SKSławomir Kujawski
Sławomir Kujawski
MSMaciej Slupski
Maciej Slupski
PZPaweł Zalewski
Paweł Zalewski
Background: This meta-analysis evaluates the overall effect of the non-pharmacological intervention, aerobic exercise, upon serum liver enzymes levels, glucose metabolism and anthropometric measures amongst patients with metabolic associated fatty liver disease (MAFLD). It also examines whether the effects on these outcomes are moderated by the aerobic training protocol when considered according to the American College of Sports Medicine (ACSM) recommended FITT (frequency, intensity, time, type) principles. Approach and Results: Fifteen randomized control trials were included in the meta-analysis. Compared with usual care, continuous and interval training showed significant efficacy in alanine aminotransferase (ALT) level improvement (MD = −2.4, 95% CI: −4.34 to −0.46 p = 0.015, I2 = 9.1%). Interventions based on all types of aerobic exercise protocols showed significant improvement of intrahepatic triglycerides (MD = −4.0557, 95% CI: −5.3711 to −2.7403, p < 0.0001, I2 = 0%) and BMI (MD = −0.9774, 95% CI: −1.4086 to −0.5462, p < 0.0001, I2 = 0). Meta-regression analysis demonstrated a significant correlation between total intervention time and ALT level (for all aerobic protocols: 6.0056, se = 2.6896, z = 2.2329, p = 0.02; as well as for continuous and interval aerobic protocols: 5.5069, se = 2.7315, z = 2.016, p = 0.04). Conclusions: All types of aerobic exercise protocols are effective at improving intrahepatic triglycerides and lead to a reduction in body mass index. In addition, continuous and interval aerobic exercise may be more effective at improving ALT ≤12 weeks intervention time benefits the management of MAFLD.

26 December 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
GRGracjan Różański
Gracjan Różański
DPDerek Pheby
Derek Pheby
JNJulia L. Newton
Julia L. Newton
Modra MurovskaModra Murovska
Modra Murovska
PZPaweł Zalewski
Paweł Zalewski
Joanna SłomkoJoanna Słomko
Joanna Słomko
Metabolic-associated fatty liver disease (MAFLD), previously called non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver disease worldwide. It is characterised by excessive fat accumulation in hepatocytes. Currently, no pharmacological therapy is effective for this disease, so non-pharmacological alternatives such as diet, supplementation or physical activity are being sought. For this reason, we reviewed the available databases to analyse the studies conducted to date using different modifications of intermittent fasting among patients with MAFLD. Eight studies using this dietary strategy were included in this review. The results obtained in the different trials are varied and do not allow a clear determination of the effect of the different types of intermittent fasting on anthropometric and biochemical parameters among patients with MAFLD. However, this type of diet seems to show some therapeutic potential, but further studies are needed.

30 July 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
GRGracjan Różański
Gracjan Różański
SKSławomir Kujawski
Sławomir Kujawski
JNJulia L. Newton
Julia L. Newton
PZPaweł Zalewski
Paweł Zalewski
Joanna SłomkoJoanna Słomko
Joanna Słomko
Metabolic-associated fatty liver disease (MAFLD), formerly non-alcoholic fatty liver disease (NAFLD), is characterized by excessive fat accumulation in hepatocytes. It is the most common chronic liver disease worldwide and is a significant public health problem. In the absence of pharmacological therapy, other treatments such as diet, physical activity, or supplementation are sought. Non-pharmacological therapies may include curcumin supplementation, which has been shown to have many health-promoting properties, including antioxidant, anti-inflammatory, and anti-cancer effects. For this reason, we reviewed available databases to analyze publications describing the effect of curcumin supplementation on biochemical parameters in MAFLD. Nine studies (eight RCTs and one CT) based solely on supplementation of patients with curcumin were included in this review. The results from the individual trials were varied and did not allow clear conclusions. Although they suggest that curcumin shows some potential in the treatment of MAFLD, further research is needed.

17 June 2022 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SKSławomir Kujawski
Sławomir Kujawski
Joanna SłomkoJoanna Słomko
Joanna Słomko
BGBeata Godlewska
Beata Godlewska
ACAgnieszka Cudnoch-Jedrzejewska
Agnieszka Cudnoch-Jedrzejewska
Modra MurovskaModra Murovska
Modra Murovska
PZPaweł Zalewski
Paweł Zalewski
Background: The aim of this study was to explore the tolerability and effect of static stretching (SS) and whole body cryotherapy (WBC) upon fatigue, daytime sleepiness, cognitive functioning and objective and subjective autonomic nervous system functioning in those with Chronic Fatigue Syndrome (CFS) compared to a control population. Methods: Thirty-two CFS and eighteen healthy controls (HC) participated in 2 weeks of a SS + WBC programme. This programme was composed of five sessions per week, 10 sessions in total. Results: A significant decrease in fatigue was noted in the CFS group in response to SS + WBC. Some domains of cognitive functioning (speed of processing visual information and set-shifting) also improved in response to SS + WBC in both CFS and HC groups. Our study has confirmed that WBC is well tolerated by those with CFS and leads to symptomatic improvements associated with changes in cardiovascular and autonomic function. Conclusions: Given the preliminary data showing the beneficial effect of cryotherapy, its relative ease of application, good tolerability, and proven safety, therapy with cold exposure appears to be an approach worth attention. Further studies of cryotherapy as a potential treatment in CFS is important in the light of the lack of effective therapeutic options for these common and often disabling symptoms.